Get started

Biotechnologystocks

Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name during the pandemic, now faces a pivotal moment. Activist investor Starboard Value has taken a $1 billion stake, signaling potential changes on the horizon. But what does this mean for Pfizer's future? The company that swiftly developed a COVID-19 vaccine now grapples with declining sales and a tumbling stock price. Starboard's involvement brings both challenge and opportunity. Will this be the catalyst for Pfizer's renaissance or a sign of deeper troubles ahead? Former Pfizer executives have been approached to assist in the turnaround effort. Their potential involvement adds an intriguing layer to this unfolding story. Could their experience and insight be the key to unlocking Pfizer's next chapter of success and innovation? As the pharmaceutical landscape evolves post-pandemic, Pfizer's response to this pressure could set industry trends. Cost-cutting, strategic refocusing and potential leadership changes loom large. How will these moves impact drug development, patient care, and the broader healthcare ecosystem? For investors, patients, and industry watchers, Pfizer's next moves are crucial. Will the company emerge stronger, leaner, and more innovative? Or will it struggle to find its footing in a rapidly changing market? The answers to these questions could reshape the future of global healthcare.
NYSE:PFELong
by signalmastermind
XBI the ETF for Biotechnology LONGBiotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend with XBI pivoting to bullish back in early November. I add long positions when I see a dip on the 3-4hr chart. My targets are the fib retracement expectation at 116 confluent with the first upper VWAP band line and then the 135-138 zone underneath the second upper line shown in thin red on the chart. This ETF smooths out the volatility characteristic of some of the smaller biotechnology firms making it safer albeit with lesser rewards expectations. Positions in NVAX and MRNA are having a good start to the week and will reflect in a small way in this ETF which has broad constituent stocks within its portfolio.
AMEX:XBILong
by AwesomeAvani
1
ALPN and VRTX may merge surge of bullish momentum LONGAlpine is a biotech stock that had an earnings report beating estimates two weeks ago. It is now reaching for all-time highs. That said, it is burning cash just slowing down the burn. Both revenue and earnings showed remarkable improvement as compared with the previous quarter. The bullish momentum of price and volume is obvious on the weeky chart with the print of a massive bullish engulfing candle. Another earnings report is due in 4 weeks. In the meanwhile, the news catalyst is VRTX and ALPN may be merging. www.tradingview.com / I will take a risky long trade here with a stop loss at 50 and a profit first target of 80 and the second at 90.
ALong
by AwesomeAvani
STRO a biotech startup flips into positive earnings LONGSTRO on a 240 minute chart got trader interest out of earnings that were projected to be net cash outflow into reported actual earnings. This is a remarkable turnaround. The RSI lines surged. The predictive algorithm which relies on a lookback of the regression line for analysis toward the future forecasts a move up much higher. I will take a long trade here seeking 50-60% in a month although the forecast is for a doubling.
NASDAQ:STROLong
by AwesomeAvani
VINC a speculative biotech penny stock LONGVINC went from 1.5 to 3.0 in less than three hours with 12X relative volume in the afternoon after a month of a slow climb from a news release that really did not amount to much. Insiders are 25% of the shareholders and that may be the story here. This could be manipulation at its finest. I have to wonder how many insiders bought how many shares and when the rug pull. This is a high tight bull flag pattern which typically results in another leg higher of the same magnitude. I suppose that is in clean trading without any manipulation. If this takes off again it might be worth trying with a small position so long as the trader can hit a button to close the full position when the sudden reversal occurs. I will trade this long with a group of moving averages to make alerts for crossing lines and slopes levelling out and see if it can go anywhere.
NASDAQ:VINCLong
by AwesomeAvani
32
VTYX falls to support on private offering Biotech LONGVTYX- Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share in a private placement to certain qualified institutional buyers in a bearish news catalyst on March 7th. I have recently uploaded my idea for VTYX on February 27th. Any traders who bought at 7.00 based on that idea may have sold on March 6th for 11.00 and achieved a 55% return in less than two weeks. On the 15 minute chart, VTYX has pulled back to support from the news catalyst. It has settled on the first upper VWAP band where it also found support in February after the post-earnings bullrun and again on February 27th when I uploaded the prior idea. VTYX is now at the bottom of a megaphone pattern ( broadening wedge) reflecting increasing volatility. The predictive algorithm from Lux Algo shows a forecast consistent with price action about the confluence of the support trendline in green and the first upper VWAP band in thick blue while the regression line and then predictive algorithm derived from it is the black line. Biotechnology especially small caps are among the hottest sectors at this time. This one went from cold to very hot and is now lukewarm while readying another bout of bullish momentum. I will revest capital from the previous 10 day trade in a long position expectant of a target of 11 or about 35-40% upside from current price.
NASDAQ:VTYXLong
by AwesomeAvani
BLUE- a biotechnology earnings penny stock LONGBLUE a week ago had a bull run to gain 90% in 5 days and then reversed into a standard Fibonacci retracement on the 30-minute chart, then in consolidation for a day or two getting support from the mean anchored VWAP. The last trading day was a quick rise with momentum in a bull flag. Earnings are coming. I will take another long trade on BLU into earnings. My target is 1.90 about the high of the prior trend up and below the second VWAP line above the mean. A tight stop loss at 1.53 ( below the flag's consolidation) will make it more likely the trade will be a 20% winner. I have taken call options strikng $1.50 for March 15th for $20 each. or a small loss of 2-3%
NASDAQ:BLUELong
by AwesomeAvani
MYO can Myomo continue the push to the earnings report?MYO had impressive week gaining over 35%. It is a volatile penny biotechnology stock with good earnings back in November new due for another report. On a 120 minute chart with relative volatility and volume indicators and a volume profile added. The volume and volativlty of this past week's move is obvious. Price gain has slowed on the approach to the POC line of the volume profile which appears to be resistance. Price may break that resistance but could get rejected there. I plan to buy MYO long on a break of resistance with a buy stop set at 4.04 and a stop loss at 3.96. If MYO rises and gets over 4.04 the order should fill and if it retests the POC line as support and the support fails, the stop will close the trade. My expectation however is for the earnings run to take it to the level of the pivot high in early January for a 25% gain.
AMEX:MYOLong
by AwesomeAvani
LEXX a penny medical stock LONGLEXX on the daily chart is on a big bullrun breaking out of an ascending broadening triangle or megaphone pattern demostrative of increasing volatility. Retlative volumes are 2X the historical comparison. Price is now on the approach to the highs of 2023 but is only 15% of the all high highs of 19 at the neckline of a head and shoulders back in 2018-2019, In short it has a lot of upside if it can show earnings growth on higher revenues. For now targets are 4.15 the high of 2022 and 6.45 the high of 2021 marked on the chart in black horizontal lines. LEXX is a money burning medical penny it is high risk like its peers. The reward potential is as much as 7X and more realistically 2X in the intermediate term. I will so long here with the risk in mind in the context of the reward potential.
NASDAQ:LEXXLong
by AwesomeAvani
SLB a rising biotechology stock LONGSLN has appreciated 70% in the past month largly on the strength of an earnings beat. Unlike many small cap biotechnology companies, SLN is actually making money and beating analyst's estimates. On the 3O minute chart, price is just below the POC line of the near term volume profile and sitting on the dynamic support of a VWAP line. Strength lines are above 50 and the low time frame green line is above its counterpart. Ovreall, I see SLN rising more after a little more consolidation. I will enter a long trade with a buy stop at 9.18 to catch a trade when price crosses over the POC line, I will set the stop loss at 9.14 below that line and target both 20% and 30% ROI in equal halves of the position.
NASDAQ:SLNLong
by AwesomeAvani
IMGN Biotech Post Earnings IMGN had great earnings the last days of April and has been trending up ever since. It is riding the upper Bollinger band consistently in this past wee. The volume spike after earnings has subsided but ongoing volume is at about 5X the moving average of early April and March. Increased volume supports price momentum. The volume spike here is obvious and significant. IMGN announced a public offering. I see this as a positive. It is primed for increasing growth but needs the fuel. Interest rates are high. Stock offering will raise cash and all shareholders will be rewarded. IMGN is resting and consolidated in a narrow range during this public offering. See also the favorable article from IBD linked below. I see IMGN as a solid swing long until the next earnings. I will watch for an uncoiling upon completion of the offering with resumption of momentum moving forward.
ILong
by AwesomeAvani
NTEC Trying ....AGAINNTEC trying to break and hold above this 786 fib level ....AGAIN. It was a previous area of support leading up to the last sell-off but since breaking below it has remained a sticky level of resistance. "Aside from the cannabis directive, the company has also built a stronger pipeline for things like cancer. In fact, late last month, a patent abstract from Decoy surfaced. It showed that this was for Decoy’s “Compositions and methods for treatment of cancer using bacteria’ and that the patent was granted. With the latest proposed merger seemingly coming to fruition, this additional piece could give the company more exposure to the mounting cancer trend in the market recently. Shares have catapulted to highs of $17.80 during the week." Read More about this Decoy/Intec Deal: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
N
by PennyStocks101
ABIO Caught Between Two FibsOn this episode of "Between Two Fibs" ABIO once again tested the 618 line plotted after using the recent low as the anchor. This has been a failure point 2 other times in the last few weeks but with a little more afternoon momentum, it will be interesting to see if it can break and hold above it. Other than that, the 786 fib appeared to have acted as lower support a few times prior to gapping down recently. With today's big swing, that could be another key level for ABIO to hold at or above. See More: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
A
by PennyStocks101
This looks...Familiar on ATOSThis is a very interesting level for ATOS right now. The last two times before this most recent instance the stock failed to break through and hold this level. It was able to do that briefly this year but unsustainable. After consolidating this last time around, what's the catalyst to actually spark a firm move? I think a lot will come down to the next steps for AT-301 to be honest: "Recently ATOS has received phase 2 initiation approval from the Swedish Medical Product Agency for its oral Endoxifen. This drug targets mammographic breast density (MBD), to reduce and eradicate potential tumors. MBD affects millions worldwide and can reduce the effectiveness of mammograms...Doctors around the world depend on mammogram studies to detect cancer through breast density. With a drug such as Endoxifen, it would increase the ability for earlier diagnosis, which in turn could reduce breast cancer incidence... This is a large breakthrough for the company and considering the incidence of breast cancer around the world, Endoxifen could be a big deal moving forward. Investors should stay up to date with any news regarding this compound, as it is Atossa’s flagship product. However, it does have a sizable pipeline that includes a Covid-19 nasal spray treatment known as AT-301." Quote Source: 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
NASDAQ:ATOS
by PennyStocks101